February 19, 2014

Total Page:16

File Type:pdf, Size:1020Kb

February 19, 2014 CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS Oversight Committee Meeting February 19, 2014 CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS Summary Overview of the February 19, 2014, Oversight Committee Meeting Please find enclosed the meeting packet for the next meeting of the CPRIT Oversight Committee to be held on Wednesday, February 19, 2014, at 10:00 AM. This summary overview of major agenda items provides background on key issues for Committee consideration. CEO Report Wayne Roberts will present the CEO’s report and address issues assigned by the Oversight Committee at the January 24th meeting including reconstituting the University Advisory Committee (UAC) and proposed dashboard metrics for the agency. Chief Scientific Officer Program Portfolio Presentation and Grant Award Recommendations Dr. Margaret Kripke will present the Program Integration Committee’s recommendations for scientific research awards. The research continuation grant recommendations are the first grant applications to be considered under the “new” review process set out by SB 149. SB 149 changed the way that grant recommendations are formally approved. A vote by two-thirds of the Oversight Committee that are present and voting (i.e. not recused because of a conflict of interest) is required to approve each funding recommendation. If two-thirds of the Oversight Committee does not vote to approve an award recommendation, then a statement explaining the reason for not following the PIC’s recommendation must be included in the meeting minutes. Product Development Officer Program Portfolio Presentation and Grant Award Recommendations Kristen Doyle, acting Product Development Officer, and Dr. Jack Geltosky, CPRIT’s Product Development Review Council Chair, will discuss CPRIT’s product development portfolio and present the Chief Executive Officer’s recommendations for product development grant awards. The applications recommended for product development grant awards were submitted to CPRIT prior to the passage of SB 149. The Oversight Committee’s consideration of these awards is governed by the review process in place at the time the applications were submitted. The Oversight Committee will not vote to approve each application recommended by the Chief Executive Officer but may reject a slate of proposed grant awards by a two-thirds vote of the Committee. Nothing limits the Oversight Committee from discussing one or more recommendations on the slates individually. Following the Committee’s ratification of the grant awards, the Committee will consider delegating authority to negotiate and execute grant contracts to the CEO and General Counsel. Because information related to the scientific research and product development grant applications recommended for funding is not publicly disclosed until the Oversight Committee meeting, the information has been made available to board members through a secure electronic portal. P.O. Box 12097 Austin, TX 78711 (512) 463-3190 Fax (512) 475-2563 www.cprit.state.tx.us Strategic Communications Contract An effective, coordinated, strategic communications program is needed to inform the public, legislature, media, health professionals, and partner organizations about CPRIT’s activities. CPRIT has completed the procurement process for the strategic communications program contract pursuant to the rules for procurement of services set forth by the Texas State Comptroller of Public Accounts. A recommendation will be presented to Oversight Committee by the Communications Officer. Scientific Research and Prevention Programs Committee Appointments The Chief Executive Officer has appointed 27 new members to the CPRIT’s Scientific Research and Prevention Programs Committee. CPRIT’s statute requires the appointments to be approved by the Oversight Committee. The appointments will be discussed by the Nominations Subcommittee at its February 17 meeting. A biographical sketch for each appointee is included in the board packet. Presentation by SRA, International Inc. SRA is CPRIT’s third party grant administrator. Dr. Rajan Munshi, Project Director, Peer Review and Science Management at SRA International, Inc. will present a summary of the professional services provided to support CPRIT’s peer review and grants management activities. The presentation will include an outline of the stages of the grant award life cycle, key aspects of these stages, and the processes that have been implemented to ensure a rigorous, robust, and transparent process for grant awards. Program Priorities Project The Oversight Committee chair will report on efforts undertaken by the chair, CEO Roberts, and Dr. Becky Garcia (staff project lead) since the January 24 meeting to frame a process for the Oversight Committee to set annual priorities for CPRIT grant programs. Executive Staff Reports Summary reports of important program, operational, and fiscal activities will be provided by the Chief Executive Officer, the Chief Prevention and Communications Officer, the Chief Operating Officer Report, and the Chief Compliance Officer. Memos from the appropriate subcommittees recommending action have been provided for items that the Oversight Committee is expected to act upon. February 19, 2014 Meeting Summary Overview Page 2 Oversight Committee Meeting Texas State Capitol Extension 1400 N. Congress Avenue, Austin, Texas 78701 Room: E1.012 February 19, 2014 10:00 a.m. The Oversight Committee may discuss or take action regarding any item on this agenda, and as authorized by the Texas Open Meetings Act, Texas Government Code Section 551.001 et seq., may meet in closed session concerning any and all purposes permitted by the Act. 1. Call to Order 2. Roll Call/Excused Absences 3. Adoption of Minutes from January 24, 2014 meeting TAB 1 4. Chief Executive Officer Report TAB 2 5. Honoraria Policy TAB 3 6. Chief Scientific Officer Report and Grant Award Recommendations TAB 4 7. Chief Product Development Officer Report and Grant Award Recommendations TAB 5 8. Chief Prevention and Communications Officer Report TAB 6 9. Strategic Communications Contract TAB 6 10. Scientific Research and Prevention Program Committee Appointments TAB 7 11. Proposed Amendment to 25 T.A.C.703.13 and Authorization to Post in the Texas Register 12. Presentation by SRA, International Inc. TAB 8 13. Program Priorities Project TAB 9 14. Subcommittee Business 15. Chief Operating Officer Report TAB 10 16. Compliance Officer Report TAB 11 17. Consultation with General Counsel 18. Future Meeting Dates and Agenda Items 19. Public Comment Anyone wishing to make public comments is required to notify the Chief Executive Officer in writing prior to the start of the meeting. The Committee may limit the time a member of the public may speak. 20. Adjourn January 24, 2014 Minutes 1. Meeting Called to Order The meeting was called to order by Chair William Rice, Friday, January 24, 2014 at 11:07 a.m., at the Capitol Extension Building, Committee Room E1.012 in Austin Texas. 2. Roll Call /Excused Absences Board Members Present: Chair William Rice Angelos Angelou Gerry Geistweidt Pete Geren Ned Holmes Cynthia Mulrow Craig Rosenfeld Amy Mitchell Chair Rice asked for a motion to grant an excused absence to Will Montgomery, whose flight was cancelled due to inclement weather. A motion was made by Mr. Geren and seconded by Mr. Holmes to grant an excused absence to Will Montgomery whose flight was cancelled due to inclement weather. MOTION CARRIED UNANIMOUSLY A quorum being present, the meeting was called to order by Chair Rice. 3. Adoption of Minutes from November 22, 2013 meeting Chair Rice entertained a motion to approve the Minutes as circulated. Motion made by Ms. Mitchell and seconded by Dr. Rosenfeld to approve the Minutes for the November 22, 2013 meeting as circulated. MOTION CARRIED UNANIMOUSLY Chair Rice informed the members that the committee would not take up the Product Development award slates scheduled to be discussed under agenda item #6 due to the absence of Dr. Jack Geltosky, Chair of the Product Development Review Council. Dr. Geltosky’s flight was cancelled due to inclement weather. The award slate has been rescheduled for the February 19th meeting. 4. Chief Executive Officer Report CEO Wayne Roberts reported on the following issues presented by the memorandum included in the Board Meeting Packet: Status and summary of CPRIT staff vacancy postings Chief Product Development Officer posting closes January 24, 2014. Internal Auditor posting extended until January 24, 2014. Attorney posting closed January 10, 2014. Procurement Specialist posting will close February 28, 2014. Grant Specialist postings are being refined and will be posted prior to February 19th Oversight Committee meeting. Chief Compliance Officer was filled December 16, 2013. Implementation of State Auditor’s Recommendations CPRIT has fully implemented or is in the process of fully implementing all 51 recommendations from the SAO’s January 2013 management audit. Annual Report The report will be submitted by January 31, 2014 and will, for the first time, meet all statutory requirements and contain no disclaimers. Electronic Bulletin Board CEO Roberts reported that changes made by the 83rd Legislature permit members of a governing body to communicate via an electronic bulletin board that is accessible through the agency’s website and viewable in real-time by the public. Mr. Geren recommended that this item be referred to the Board Governance Subcommittee for consideration. A motion to refer the electronic bulletin board to the Board
Recommended publications
  • (R&D) Tax Credit
    Report toThe the Pennsylvania Pennsylvania Department of General Revenue Assembly Bureau of Research on the Research and Development (R&D) Tax Credit The Pennsylvania Department of Revenue Bureau of Research March 15, 2012 Pennsylvania Research and Development Tax Credit Page 1 of 14 The Pennsylvania R&D Tax Credit Statute On May 7, 1997, Act 7 of 1997 created the Pennsylvania research and development (R&D) tax credit. The R&D tax credit provision became Article XVII-B of the Tax Reform Code of 1971 (TRC). The intent of the R&D tax credit was to encourage taxpayers to increase R&D expenditures within the Commonwealth in order to enhance economic growth. The terms and concepts used in the calculation of the Commonwealth’s R&D tax credit are based on the federal government’s R&D tax credit definitions for qualified research expense.1 For R&D tax credits awarded between December 1997 and December 2003, Act 7 of 1997 authorized the Department of Revenue (Department) to approve up to $15 million in total tax credits per fiscal year. Additionally, $3 million of the $15 million was set aside for “small” businesses, where a “small business” is defined as a “for-profit corporation, limited liability company, partnership or proprietorship with net book value of assets totaling…less than five million dollars ($5,000,000).” Over the years, several changes have been made to the R&D tax credit statute. Table 1 lists all of the acts that have changed the R&D tax credit statute, along with the applicable award years, the overall tax credit cap and the “small” business set aside.
    [Show full text]
  • Drug Repositioning: Extracting Added Value from Prior R&D Investments
    Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. InsightPharmaReports.com Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. Published in July 2010 by Cambridge Healthtech Institute • www.InsightPharmaReports.com • Reproduction prohibited i Insight Pharma Reports is a division of Cambridge Healthtech Institute, a world leader in life science information and analysis through conferences, research reports, and targeted publications. Insight Pharma Reports focus on pharmaceutical R&D—the technologies, the companies, the markets, and the strategic business impacts. They regularly feature interviews with key opinion leaders; surveys of the activities, views, and plans of individuals in industry and nonprofit research; and substantive assessments of technologies and markets. Managers at the top 50 pharma companies, the top 100 biopharma companies, and the top 50 vendors of tools and services rely on Insight Pharma Reports as a trusted source of balanced and timely information. Related Report Data Mining in Drug Development and Translational Medicine by Hermann A.M. Mucke, Ph.D. General Manager: Alfred R. Doig, Jr. 781-972-1348, [email protected] Editorial Operations Director: Laurie Sullivan 781-972-1353, [email protected] Design Director: Tom Norton 781-972-5440, [email protected] Production Director: Ann Handy 781-972-5493, [email protected] Marketing Manager: James Prudhomme 781-972-5486, [email protected] Customer Service: Rose LaRaia 781-972-5444, [email protected] Corporate Subscriptions: David Cunningham 781-972-5472, [email protected] Global Report Sales: Jack Valeri 781-972-1355, [email protected] Insight Pharma Reports, 250 First Ave., Suite 300, Needham, MA 02494 www.InsightPharmaReports.com ii • www.InsightPharmaReports.com • Reproduction prohibited Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M.
    [Show full text]
  • (R&D) Tax Credit
    Report to theThe Pennsylvania Pennsylvania Department General of Revenue Assembly Bureau of Research on the Research and Development (R&D) Tax Credit The Pennsylvania Department of Revenue Bureau of Research March 15, 2010 Pennsylvania Research and Development Tax Credit Page 1 of 15 The Pennsylvania R&D Tax Credit Statute As part of the Fiscal Year 2009-10 budget, Act 48 of 2009 reduced the amount of tax credits available under several tax credit programs that can be awarded during the following two years. Act 48 reduced the total amount of R&D tax credit available in FY 2009-10 from $40 million to $20 million and in FY 2010-11 from $40 million to $18 million. Starting in FY 2011-12, the total amount of R&D tax credit the Department can award returns to $40 million per year. ******** On May 7, 1997, Act 7 of 1997 created the Pennsylvania research and development (R&D) tax credit. The R&D tax credit provision became Article XVII-B of the Tax Reform Code of 1971 (TRC). The intent of the R&D tax credit was to encourage taxpayers to increase R&D expenditures within the Commonwealth in order to enhance economic growth. The terms and concepts used in the calculation of the Commonwealth’s R&D tax credit are based on the federal government’s R&D tax credit definitions for qualified research expense.1 Over the years, several changes have been made to the R&D tax credit statute. On December 23, 2003, Governor Edward G. Rendell signed Act 46 of 2003 into law.
    [Show full text]
  • יומן הפטנטים והמדגמים Patents and Designs Journal
    י /' התשס"ח 5/2008 רשומות ISRAEL STATE RECORDS ו' באב התשס"ח August 7, 2008 יומן הפטנטים והמדגמים PATENTS AND DESIGNS JOURNAL פטנטים עמוד PATENTS Page בקשות שהוגשו Applications filed 1507 בקשות שקובלו Applications accepted 1775 פטנטים שניתנו Patents granted 1992 פטנטים שחודשו Patents renewed 1993 פטנטים שתוקפם פקעו Patents not in force 1995 פטנטים שחודשו לעשרים שנה Patents renewed for 20 years 1996 פטנטים שפג תוקפם Patents expired 1997 הודעות Notices 1998 שינויים בפרטים רשומים Changes in particulars entered בפנקס in register 2001 תיקוני טעויות Corrigenda 2002 מפתחות לבקשות שקובלו Indices of applications accepted i מדגמים DESIGNS מדגמים שנרשמו Designs registered 2004 מדגמים שחודשו Designs renewed 2017 מדגמים שבוטלו Designs void 2018 ו' באב התשס"ח – August 7, 2008 1507 ידיעות כלליות מכתבים, מסמכים, וכו' בענייני פטנטים ומדגמים יש לשלוח אל: רשם הפטנטים והמדגמים, רח' הסדנא 4, ירושלים לשכת הפטנטים נמצאת ברח' הסדנא 4, תלפיות, ירושלים והיא פתוחה לציבור בימי חול שאינם ערבי שבת או מועד בין השעות 8:30 ו - 12:30. לשכת הפטנטים מספקת תצלומים של פירוטים ושרטוטים במחיר של 2.50 שקלים בעד כל עמוד או חלק ממנו. אגרות ללשכת הפטנטים מתקבלות אך ורק על ידי תשלום לחשבון הלשכה בבנק הדואר מס' 0-24145-2. יש להציג קבלת בנק הדואר ללשכה יחד עם הבקשה לפעולה שעבורה האגרה שולמה. GENERAL INFORMATION Letters, documents, etc. concerning Patents and Designs should be addressed to: The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs.
    [Show full text]
  • Collaborative Drug Discovery's 10 Anniversary Community Meeting
    Collaborative Drug Discovery’s 10th Anniversary Community Meeting April 4th, 2014 8am-6pm UCSF Mission Bay Conference Center 1675 Owens St. San Francisco, CA 94158 Please use this Twitter hashtag for the event: #CDDx14 Agenda 7:45 Registration - refreshments in Foyer and Exhibition room 8:15 Opening Remarks - with UCSF Host, Stephanie Robertson and CDD CEO, Barry Bunin Collaborative Workflow: Basic and Advanced Use Cases of CDD Vault 8:20 Charlie Weatherall (CDD) & Anna Spektor (CDD) 9:10 Morning Sessions - moderated by Sylvia Ernst (CDD) The Rockefeller University Compound Screening Library 9:15 J. Fraser Glickman (Rockefeller University) Recent Progress in De-Orphanization of Nuclear Receptors 9:40 Ruo Steensma (Orphagen Pharmaceuticals) 10:05 Morning Break - located in the Foyer and Exhibition room Large small molecules in a Small large molecule world 10:35 Leanna Staben (Genentech) Linking the Molecular Structure of Medicines to their Biological Effects 11:00 Bob Volkmann (Systamedic & Mnemosyne Pharmaceuticals) Panel: Externalized Research - What Makes a Good Partnership? Wisdom from Experts 11:25 Who've "Been There - Done That," moderated by Sylvia Ernst (CDD) 11:50 Lunch - boxed lunches in the Foyer and Exhibition room Optional: “What if CDD had...” provide feedback to our product team (12:35) Kellan Gregory (CDD) 10 Years Evolving Our Collaborative Drug Discovery Vaults 1:05 Barry Bunin (CDD) CDD Vault: Noteworthy recent enhancements and a preview of things to come 1:30 David Blondeau (CDD) & Kellan Gregory (CDD) 2:20 Afternoon sessions - moderated Christopher Lipinski The Tuberculosis Drug Accelerator: A New Paradigm For Drug Discovery 2:25 Jerry Shipps (Tuberculosis Drug Accelerator) The role of NIAID in the development of therapeutics for Infectious Diseases 2:50 Martin John Rogers (NIAID) 3:15 Afternoon Break - located in the Foyer and Exhibition Room Targeting the Immunoproteasome 3:40 Dustin L.
    [Show full text]
  • Årsredovisning Med Information Från Form 20-F 2008 Inledning 2
    ASTRAZENECA – ÅRSREDOVISNING MED INFORMATION FRÅN FORM 20-F 2008 INLEDNING 2 AstraZeneca och året i korthet 2 Utvecklingen i sammandrag 2 Ordföranden har ordet 4 Koncernchefens översikt 5 FÖRVALTNINGSBERÄTTELSE 8 FÖRVALTNINGSBERÄTTELSE 8 Inledning 8 Omvärldsanalys 9 Strategi, mål och mätetal 12 > Mäta våra resultat 14 > Vår utveckling – Ekonomiska och övriga nyckeltal 15 Resurser, kompetenser och möjligheter 16 > Läkemedel 16 > Forskning och utveckling 17 > Forsknings- och utvecklingsportfölj den 29 januari 2009 22 BOKSLUT 98 > Försäljning och marknadsföring 25 >6 Immateriella rättigheter 2 > Varuförsörjning och produktion 27 > Medarbetare 28 Ekonomisk översikt 31 > Rapporteringsprinciper 31 > Verksamhetsbakgrund och viktiga händelser 2008 32 > Kortfattad analys av perioden jan–dec 2008 33 > Finansiell ställning , inklusive kassafl öde och likviditet – 2008 35 > Omstrukturerings- och synergi- RAPPORT OM ERSÄTTNINGAR 174 kostnader 36 > Kapital och aktieavkastning 37 > Framtidsutsikter 37 > Kortfattad analys av perioden jan–dec 2007 38 > Finansiell ställning, inklusive kassafl öde och likviditet – 2007 40 > Hantering av fi nansiella risker 41 > Viktiga redovisningsprinciper och bedömningar 43 > Övrig redovisnings information 47 YTTERLIGARE INFORMATION 190 VIKTIG INFORMATION FÖR LÄSARE som var tillgänglig vid utarbetandet av denna Användandet av redovisad utveckling, fasta AV DENNA REDOVISNING årsredovisning med information från Form 20-F och valutakurser och ekonomiska mått för kärn- företaget åtar sig inget ansvar för att uppdatera dessa verksamheten framåtriktade kommentarer. Vi identifi erar framåtriktade I förvaltningsberättelsen och i avsnittet Utvecklingen i Risker beträffande framåtriktade kommentarer kommentarer genom ord som till exempel ”förutse”, sammandrag på sidorna 2 och 3 hänvisas till följande Syftet med denna årsredovisning med information från ”tror”, ”förväntar”, ”avser” och snarlika uttryck i sådana mått: Form 20-F är att tillhandahålla information till företagets kommentarer.
    [Show full text]
  • (R&D) Tax Credit
    Report toThe the Pennsylvania Pennsylvania Department of General Revenue Assembly Bureau of Research on the Research and Development (R&D) Tax Credit The Pennsylvania Department of Revenue Bureau of Research March 15, 2016 Pennsylvania Research and Development Tax Credit Page 1 of 14 The Pennsylvania R&D Tax Credit Statute On May 7, 1997, Act 7 of 1997 created the Pennsylvania research and development (R&D) tax credit. The R&D tax credit provision became Article XVII-B of the Tax Reform Code of 1971 (TRC). The intent of the R&D tax credit was to encourage taxpayers to increase R&D expenditures within the Commonwealth in order to enhance economic growth. The terms and concepts used in the calculation of the Commonwealth’s R&D tax credit are based on the federal government’s R&D tax credit definitions for qualified research expense.1 For R&D tax credits awarded between December 1997 and December 2003, Act 7 of 1997 authorized the Department of Revenue (Department) to approve up to $15 million in total tax credits per fiscal year. Additionally, $3 million of the $15 million was set aside for “small” businesses, where a “small business” is defined as a “for-profit corporation, limited liability company, partnership or proprietorship with net book value of assets totaling…less than five million dollars ($5,000,000).” Over the years, several changes have been made to the R&D tax credit statute. Table 1 lists all of the acts that have changed the R&D tax credit statute, along with the applicable award years, the overall tax credit cap and the “small” business set aside.
    [Show full text]
  • 11.Absfrontpageduality ADA 13.Indd
    PRESENTED AND PUBLISHED ABSTRACTS DISCLOSURE INFORMATION All presenters/authors are required to disclose to the program audience any fi nancial relationships related to the subject matter of this program. The intent of this disclosure is not to prevent a presenter or author from being involved in the activity, but rather to provide participants with information on which they may make their own judgments. AUTHOR DISCLOSURE A829 AUTHOR DISCLOSURE A830 ABSTRACT AUTHOR DISCLOSURE INFORMATION AUTHOR RELATIONSHIP/COMPANY AUTHOR RELATIONSHIP/COMPANY Aakhus, Svend ...................................... Disclosed no confl ict of interest. Adhami, Anwar .................................... Disclosed no confl ict of interest. Aalgur, Fusun ........................................Disclosed no confl ict of interest. Adhami, Mitra ......................................Disclosed no confl ict of interest. Aamidor, Sarah E. .................................Disclosed no confl ict of interest. Adhya, Sumona .................................... Employee: Medtronic Abayomi, Julie ..................................... Disclosed no confl ict of interest. Adkins, Laura ........................................ Disclosed no confl ict of interest. Abbas, Afroze .......................................Disclosed no confl ict of interest. Adler, Benjamin ....................................Disclosed no confl ict of interest. Abbasi, Fahim ....................................... Disclosed no confl ict of interest. Adler, Steffen ....................................... Consultant:
    [Show full text]
  • 專利條例第 20 條發表的指定專利申請記錄請求 Requests to Record Designated Patent Applications Published Under Section 20 of the Patents Ordinance
    香港知識產權公報 Hong Kong Intellectual Property Journal 2017年5月5日 5 May 2017 公報編號 Journal No.: 736 公布日期 Publication Date: 05-05-2017 分項名稱 Section Name: 目錄 Contents 目錄 Contents 根據專利條例第 20 條發表的指定專利申請記錄請求 Requests to Record Designated Patent Applications published under section 20 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按申請人姓名/名稱排列 Arranged by Name of Applicant 根據專利條例第 27 條發表批予標準專利 Granted Standard Patents published under section 27 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按專利所有人姓名/名稱排列 Arranged by Name of Proprietor 1/359 公報編號 Journal No.: 736 公布日期 Publication Date: 05-05-2017 分項名稱 Section Name: 目錄 Contents 根據專利條例第 118 條發表批予短期專利 Granted Short-term Patents published under section 118 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按專利所有人姓名/名稱排列 Arranged by Name of Proprietor 根據專利條例(第 514 章)公布的其他公告 Other Notices Published under the Patents Ordinance (Cap. 514) 根據專利條例第 20 條發表後撤回,當作已予撤回或被拒的申請 Applications withdrawn, deemed to have been withdrawn, or refused, after publication under section 20 of the Patents Ordinance 根據專利條例第 39 條,標準專利因未繳續期費而停止有效 Standard Patents Ceased through Non-payment of Renewal Fees under section 39 of the Patents Ordinance 根據專利條例第 39(1)(b)條,標準專利
    [Show full text]
  • Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review
    Drug Discovery Therapeutic Drug Repurposing, Repositioning and Rescue Part II: business review There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable. The activity and productivity of DRPx focused companies as well as pharmaceutical company efforts appear to offer some encouragement in providing solutions to the myriad of problems the industry faces at the present time. These efforts can only be sustained and expanded if the dynamic variables of viable and creative business models are identified and understood. In this work we describe the lessons that can be learnt from surveying the landscape of the DRPx industry. This analysis includes both the successes and the failures of past DRPx companies. We introduce the various stakeholders that are shifting the decision process of DRPx implementation and acceptance away from the pharmaceutical industry. In addition the component pieces necessary to enhance the value of a DRPx company are discussed and the top 10 mini- blockbuster and blockbuster DRPx drugs are introduced. Finally, we assess and compare an assortment of DRPx business models and evaluate the current climate of the DRPx industry. confluence of pharmaceutical company enue-generating products, which, in turn has By Dr Stephen intransigence and conservatism has con- resulted in significant R&D personnel lay-offs. Naylor, David M. A spired to increase drug discovery and This prolonged lack of pharmaceutical productivi- Kauppi and Judge M. development (DDD) cost, cycle time and risk. This ty and stifled innovation has coincided with Schonfeld trifecta of woes has been exacerbated by aggressive demands for faster delivery of better, safer and generic drug company activity and on-going cheaper drugs by patients and healthcare systems.
    [Show full text]
  • Biotech Bulletin, 2020 Volume 8
    The Life Sciences Executive Network At Sarian Strategic Partners Presents Biotech Bulletin | 2020, Volume 8 Tracking The Pulse Of The Philadelphia Life Sciences Industry Table Of Contents Stay up to date on the pulse of the Philadelphia Life Sciences industry with our Biotech Bulletin. This is a quarterly newsletter with data and 1. Isolating U.S. Drug Supply Chain is the Wrong perspectives from local leaders within the industry. Greg Sarian of Sarian Prescription for America Strategic Partners is the author of the Biotech Bulletin. Each issue will include 2. A Spotlight Conversation insight on the latest industry trends, performance metrics on local biotech with Andrew Reaume of companies, as well as current acquisitions and IPO news in this area. Melior Discovery 3. Rockland Immunochemicals, Inc. Isolating U.S. Drug Supply Chain is the 4. Creating a Successful Outcome when growing a start up Wrong Prescription for America towards a transaction By Ivana Wolfe, Bravo Group 5. Sarian Strategic Partners Biotech Index The COVID-19 pandemic has shone a spotlight on the global 6. Philly Fundings drug manufacturing process, spawning a raft of federal proposals to require all components of pharmaceuticals and medical equipment to be Founder sourced and manufactured solely on American soil with American goods. Although strengthening and supporting domestic manufacturing is a worthy cause, these proposals not only ignore basic facts but will lead to drug shortages, increased costs for businesses and consumers, and possible global retaliation. A great myth in America at the moment is that we are inextricably dependent upon China for most of our prescription drug supply.
    [Show full text]
  • Final Program
    The 9th Annual Conference of the International Chemical Biology Society ICBS2020VIRTUAL Addressing Therapeutic Challenges Together with Chemical Biology November 11, 2020 7:30 PM to 11:30 PM EST November 12, 2020 9:30 AM to 2:00 PM EST November 13, 2020 9:30 AM to 2:40 PM EST 9th Annual Conference | November 11-13, 2020 | Virtual Table of Contents Table of Contents ............................................................ 1 Session 3: Academic-Industry Partnerships Acknowledgements ........................................................ 1 case studies .................................................................... 23 ICBS Board of Directors ................................................ 2 Session 4: Chemical Biology of Small Molecule About ICBS ...................................................................... 2 Protein Degraders ........................................................ 28 ICBS International Advisory Board ............................. 3 EFMC Speaker .............................................................. 32 ICBS Global Council ...................................................... 4 Session 5: Chemical Technologies to Promote Welcome Letter ............................................................... 5 Drug Discovery ............................................................. 33 Trainee Pre-Conference Program ................................ 6 Rising Stars Session ...................................................... 37 Detailed Program ..........................................................
    [Show full text]